Rhythm PharmaceuticalsRYTM -0.49%56 Days Payable is 167.32 as of Mar. 2026, which is 32% below its 10-year median of 246.01. GuruFocus rates RYTM with a GF Score™ of 56/100 and a GF Value™ of $110.90 (Fairly Valued). The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, Rhythm Pharmaceuticals ranks better than 64.49% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rhythm Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rhythm Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (RYTM) has a Days Payable of 167.32 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rhythm Pharmaceuticals and its competitors. This is 32% below median its historical median of 246.01. Over the past decade, Rhythm Pharmaceuticals' Days Payable has ranged from 189.96 to 3,240.82. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #250 out of 704 companies in the Biotechnology industry, placing it in the top 35.5%.
Is Rhythm Pharmaceuticals' Days Payable too high?
Rhythm Pharmaceuticals' current Days Payable of 167.32 is 32% below median its 10-year median of 246.01. Over the past 10 years, this metric has ranged from a low of 189.96 to a high of 3,240.82. The Biotechnology industry median Days Payable is 113.56. Rhythm Pharmaceuticals' value of 167.32 is 47.3% above this industry median. Based on the distribution chart, Rhythm Pharmaceuticals ranks #250 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Days Payable compare to MIRM and SYRE?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #250 out of 704 companies for Days Payable. This puts Rhythm Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 113.56. Rhythm Pharmaceuticals' value of 167.32 is 47.3% above this benchmark. Historically, Rhythm Pharmaceuticals' own Days Payable has ranged from 189.96 to 3,240.82 over the past decade. While the company's 10-year median is 246.01 vs. the industry median of 113.56, Rhythm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Pharmaceuticals's current Days Payable of 167.32 is 47.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rhythm Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Pharmaceuticals's current Days Payable is 167.32, which is 32% below median its own 10-year median of 246.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Fairly Valued. The stock's GF Value™ is $110.90, compared to a current price of $110.42 — trading 0.4% below its estimated fair value. The current Days Payable is 167.32, which is 32% below median its 10-year median of 246.01 and 47.3% above the Biotechnology industry median of 113.56. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Days Payable is 167.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of $110.42 is trading 0.4% below its estimated GF Value™ of $110.90.
GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.
Key valuation signals for RYTM:
Days Payable: 167.32 (32% below median its 10-year median of 246.01)
GF Value™: $110.90 vs. price of $110.42 (0.4% below fair value)
Industry Position: 47.3% above the Biotechnology median (#250 of 704)
No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score
Get the complete analysis for RYTM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYTM has been successfully added to your 
